Vitamin E treatment in pediatric obesity-related liver disease: A randomized study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 38, Issue 1, 2004, Pages 48-55

  Vajro, Pietro ^a,b   Mandato, Claudia ^a   Franzese, Adriana ^a   Ciccimarra, Edmondo ^a   Lucariello, Stefania ^a,b   Savoia, Marcella ^a   Capuano, Grazia ^a   Migliaro, Fiorella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b European Laboratory for the Investigation of Food Induced Diseases   (Italy)

Author keywords

Antioxidants; Hepatic steatosis; Nonalcoholic fatty liver disease (NAFLD); Obesity related liver dysfunction; Vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIOXIDANT; PLACEBO; ASPARTATE AMINOTRANSFERASE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; FATTY LIVER; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER FIBROSIS; LOW CALORY DIET; MALE; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; WEIGHT REDUCTION; BLOOD; BODY MASS; CHILD; DIET THERAPY; DOSE RESPONSE; ECHOGRAPHY; ENZYMOLOGY; LIVER; LIVER DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CHILD; DIET, REDUCING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; OBESITY; PATIENT COMPLIANCE; SINGLE-BLIND METHOD; TRANSAMINASES; TREATMENT OUTCOME; VITAMIN E;

EID: 3142634597     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200401000-00012     Document Type: Article

References (40)

1. Sokol RJ. The chronic disease of childhood obesity: the sleeping giant has awakened. J Pediatr 2000;136:711-3.
2. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-43.
3. Byron D, Minuk GY. Profile of an urban hospital-based practice. Hepatology 1996;24:813-5.
4. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-32.
5. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;124:239-41.
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
7. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-4.
8. Kinugasa A, Tsunamoto K, Furukawa N, et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984;3:408-14.
9. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
10. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
11. Mod Wing RR, Greeno CG. Behavioural and psychosocial aspects of obesity and its treatment. Baillieres Clin Endocrinol Metab 1994;8:689-703.
12. Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000;136:739-43.
13. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non alcohol induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
14. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18-25.
15. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36:403-9.
16. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
17. Lavine JE. Relative antioxidant deficiency in obese children: a weighty contributor to morbidity? J Pediatr 1999;134:132-3.
18. Strauss RS. Comparison of serum concentration of α-tocopherol and β-carotene in a cross sectional sample of obese and non obese children (NHANES III). J Pediatr 1999;134:160-5.
19. Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001;34:13-8.
20. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-8.
21. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-72.
22. Gulbahar O, Karasu ZA, Ersoz G. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine [abstract]. Gastroenterology 2000;118:973.
23. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-7.
24. Fu CS, Esrason K, Alshak NS, et al. Dietary lecithin, antioxidant, and vitamin B complex (LAB) decrease hepatic steatosis on patients with non-alcoholic steatohepatitis [abstract]. Gastroenterology 1998;114:A1243.
25. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity. Arch Dis Child 1966;41:613-35.
26. Must A, Dallal GE, Dietz WH. Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2)-a correction. Am J Clin Nutr 1991;54:773.
27. Horlick M. Editorial: Body mass index in childhood-measuring a moving target. J Clin Endocrinol Metab 2001;86:4059-60.
28. Vuilleumier JP, Keller HE, Gysel D, et al. Clinical chemical methods for the routine assessment of the vitamin status in human populations. Part I: the fat-soluble vitamins A and E and β-carotene. Intern J Nutr Res 1983;53:265-72.
29. Belisario MA, Azar G, Oriani G, et al. Simultaneous evaluation of vitamins A and E in human plasma by normal phase HPLC. Boll Soc Ital Biol Sper 1993;69:641-7.
30. Snedecor GW, Cochran WG. Statistical Methods. 8th ed. Ames, Iowa: The Iowa State University Press; 1989.
31. Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology 1998;114:842-5.
32. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-6.
33. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going. Gut 2002;50:585-8.
34. Vendemiale G, Grattagliano I, Altomare E. An up-to-date on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999;29:49-55.
35. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
36. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardio. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
37. Harbeth B, Spyckerelle Y, Dechamps JP. Determinants of plasma retinol β-carotene and α-tocopherol during adolescence. Am J Clin Nutr 1991;54:884-9.
38. Marchesini G, Brizi M, Bianchi G, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-4.
39. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52.
40. Bove KE, Kosmetatos N, Wedig KE, et al. Vasculopathic hepatotoxicity associated with E-Ferol syndrome in low-birth-weight infants. JAMA 1985;254:2422-30.